Wayne Kuznar
Articles
Rechallenge With Olaparib Maintenance Improves PFS in Heavily Pretreated Ovarian Cancer
September 21, 2021
Article
Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved PFS in heavily pretreated patients with relapsed ovarian cancer.
Combination Therapy Bests Standard of Care in BRAF+ CRC
January 28, 2020
Article
Encorafenib (Braftovi) plus cetuximab (Erbitux) with or without binimetinib (Mektovi) demonstrated longer maintenance of quality of life (QoL) on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.
Early Steroid Use Reduces Cytokine Release Syndrome Risk With Axi-Cel Treatment
December 09, 2019
Article
Steroid use while cytokine release syndrome (CRS) and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurologic events.
Atezolizumab Plus T-DM1 Improves Overall Survival in Breast Cancer Subgroup
September 29, 2019
Article
Atezolizumab, along with T-DM1, showed benefit for a subgroup of patients with breast cancer.
Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer
January 24, 2019
Article
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer (BTC) who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.
Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC
January 23, 2019
Article
Preliminary findings from the SLI phase of the BEACON CRC trial show tri-drug combo has durable response in patients with BRAF V600E-mutant metastatic CRC.
Venetoclax Has Impressive Activity in ER+ and BCL-2+ Breast Cancer
January 05, 2019
Article
Combining the BCL-2 inhibitor venetoclax (Venclexta) with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor (ER)–positive and BCL-2–positive metastatic breast cancer.
Trastuzumab Biosimilar CT-P6 Shows Comparable Efficacy at 2-Year Follow-up
December 28, 2018
Article
CT-P6, a proposed biosimilar to trastuzumab, exhibited long-term disease-free survival (DFS) and overall survival (OS) similar to the reference product in the treatment of patients with HER2-positive early breast cancer.
CAR T-Cell Therapy Shows Early Potential in TNBC
December 27, 2018
Article
Chimeric antigen receptor (CAR) T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo, according to first in-human study of CAR T cells in patients with solid tumors.